GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation...

GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric Cannabinoid Therapy BALTIMORE, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTCQB: GCAN) a cannabis innovator specializing in the development of pharmaceutical and...

Pivot Files Three New Provisional Patents for the Delivery of Cannabinoids VANCOUVER, British Columbia, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Pivot Pharmaceuticals Inc. (CSE:PVOT) (OTCQB:PVOTF) (“Pivot” or the “Company”), is pleased to announce that it has filed three...

Pivot Pharmaceuticals To Commence Trading on CSE VANCOUVER, British Columbia, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Pivot Pharmaceuticals Inc. (OTCQB:PVOTF) (“Pivot” or the “Company”), an emerging biopharmaceutical company, is pleased to announce that...